When Eli Lilly reports fourth-quarter earnings on Tuesday, February 4th, the Indianapolis-based pharmaceutical giant will do so as a $1 trillion company—a valuation that seemed unimaginable just three years ago. The transformation has been driven almost entirely by two drugs: Mounjaro for diabetes and Zepbound for obesity. Together, they've created the fastest-growing pharmaceutical franchise in history.

Analysts expect Eli Lilly to report earnings per share of approximately $5.30 on revenue near $14.5 billion for the quarter. But the headline numbers matter less than the trajectory of the obesity drug business and management's outlook for 2026. At current valuations, Eli Lilly prices in years of exceptional growth—and any stumble could prove costly.

The Blockbuster Engine

Tirzepatide, the molecule behind both Mounjaro and Zepbound, has emerged as one of the most successful drug launches ever. The dual GIP/GLP-1 receptor agonist produces weight loss averaging 15-20%—roughly double what earlier drugs achieved—while also improving blood sugar control, cardiovascular outcomes, and potentially sleep apnea.

Q4 expectations for the franchise:

  • Mounjaro: Approximately $6.55 billion in quarterly sales (up ~90% year-over-year)
  • Zepbound: Approximately $3.62 billion in quarterly sales (launched December 2023)
  • Combined: Over $10 billion from one molecule in a single quarter

For context, no drug in history has reached $10 billion in quarterly sales this quickly. The total addressable market—obesity affects 42% of American adults—dwarfs anything pharmaceuticals have previously encountered.

Market Dominance

Eli Lilly has systematically captured market share from rival Novo Nordisk, whose Wegovy and Ozempic once defined the GLP-1 category:

  • New obesity prescriptions: Zepbound holds 71% share of new scripts
  • Total injectable market: Eli Lilly drugs account for nearly 60% of prescriptions
  • Growth trajectory: Lilly gained share for the fifth consecutive quarter in Q3

The competitive advantage stems from Zepbound's superior efficacy. In head-to-head trials, tirzepatide produced greater weight loss than semaglutide (Wegovy's active ingredient). Patients and doctors have responded accordingly.

"Eli Lilly has essentially solved the pharmaceutical industry's holy grail: a drug that addresses a massive chronic condition with clear, measurable results that patients desperately want. The demand is unlike anything we've seen."

— Biotech analyst at Leerink Partners

The Valuation Question

At approximately $1 trillion in market cap, Eli Lilly trades at roughly 45 times forward earnings—a premium that would have been unthinkable for a pharmaceutical company before the obesity drug revolution. The stock has risen 459% over the past five years, far outpacing even the best-performing tech giants.

Bulls argue the valuation is justified:

  • Market size: Over 100 million Americans are obese; global numbers are even larger
  • Chronic usage: Weight loss drugs require ongoing treatment, creating recurring revenue
  • Pipeline: Oral tirzepatide, combination drugs, and next-generation molecules extend the franchise
  • Pricing power: Limited competition allows premium pricing

Bears counter with concerns:

  • Competition coming: Dozens of obesity drugs are in development, including potentially superior options
  • Insurance pushback: Payers are increasingly restricting coverage and demanding discounts
  • Manufacturing constraints: Scaling production has limited revenue; any supply issues would hurt
  • Peak obesity: If the addressable population stabilizes or declines, growth will moderate

The 2026 Outlook

Analysts project Eli Lilly's 2026 earnings could reach $33.25 per share—up from an estimated $23.85 in 2025. That 40% growth would be extraordinary for a company this size, but Lilly has consistently exceeded expectations.

Key catalysts for 2026:

Oral tirzepatide (orforglipron). A pill version of the Mounjaro/Zepbound molecule could dramatically expand the market. Many patients dislike weekly injections; an oral option would eliminate that barrier. Approval could come in late 2026.

Manufacturing expansion. Eli Lilly has invested over $18 billion in new production capacity, including a $3.5 billion Pennsylvania plant announced recently. As capacity comes online, supply constraints should ease.

International expansion. The obesity drug market outside the U.S. remains largely untapped. Regulatory approvals and reimbursement negotiations in Europe and Asia could unlock substantial growth.

New indications. Tirzepatide is being studied for heart failure, fatty liver disease, and other conditions. Additional approvals would expand the patient population significantly.

What to Watch Tuesday

Beyond the headline numbers, Tuesday's earnings call will be scrutinized for several key points:

  • 2026 guidance: Management's revenue and earnings outlook will set expectations for the year
  • Capacity updates: Any supply chain improvements or constraints will move the stock
  • Pricing trends: Net price realization after rebates and discounts reveals true economics
  • Pipeline progress: Updates on oral tirzepatide and next-generation molecules
  • Competitive positioning: How is Lilly responding to emerging competition?

Investment Considerations

For investors, Eli Lilly presents a classic growth-versus-valuation dilemma. The company's competitive position is formidable, the market opportunity is enormous, and execution has been exceptional. But the stock prices in much of this success already.

For long-term investors: Lilly remains a core holding in many portfolios despite the valuation. The obesity drug market's multi-decade growth potential could justify today's premium. Dollar-cost averaging smooths entry point risk.

For value-conscious investors: Waiting for a pullback offers better risk-reward. Pharmaceutical stocks can drop 20-30% on disappointing trial results or competitive threats. Patience may be rewarded.

For income investors: Lilly's 0.6% dividend yield reflects the growth orientation. Those seeking income should look elsewhere.

Tuesday's report won't definitively answer whether Eli Lilly deserves its $1 trillion valuation. But it will provide the latest evidence in what has become one of the most compelling investment stories in modern pharmaceutical history. The obesity drug revolution has arrived—the only question is how long it lasts and how much of the upside remains.